Home/ Supplements/ Vitamin K/ Vitamin K-2 MK-4 100 mcg

Vitamin K-2 MK-4 100 mcg

product on market Capsule Biophix Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Vitamin K2 is supported by strong evidence for promoting calcium deposition in bones and preventing arterial calcification. Alfalfa is often used as a carrier or source of nutrients, though research on its specific therapeutic benefits is more limited. This formulation maintains a high safety profile for general use.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Vitamin K-2 MK-4 100 mcg
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Vegetable Capsule(s)
Serving Size
200
Servings
Botanical with Nutrients
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

100 mcg (83% DV)
Within RDA (0.8× RDA) 275 studies (A:9, B:175)
Alfalfa
300 mg

Other Ingredients

Cellulose Rice Flour Silica
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested usage: As a dietary supplement, for adults, take 1 veg capsule daily, preferably with meals.

Warnings & Precautions

Caution: For adults only.

Consult physician if pregnant/nursing, taking medication (especially anti-coagulant drugs such as warfarin, coumadin, heparin), or have a medical condition.

Keep out of reach of children.

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, or tree nut ingredients. Produced in a GMP facility that processes other ingredients containing these allergens.

Do not eat freshness packet. Keep in bottle.

Formulation Notes

Research indicates that vitamin K-2 may support healthy bones and cardiovascular health.

We included Alfalfa in our formula to provide additional support.

- Enriched with 300 mg of Alfalfa Vitamin

- Vegetarian/Vegan formula

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, or tree nut ingredients.

Additional Information

Manufactured in a GMP inspected facility Made in USA

GMP Tested

Store in a cool, dry place after opening.

Please recycle.

Metadata

Product Details

UPC / SKUX00156D051
DSLD Entry Date2021-11-19
Product TypeBotanical with Nutrients
FormCapsule
BrandBiophix
DSLD ID262195
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.